| Year |
Citation |
Score |
| 2010 |
Xu H, Krystal GW. Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4392-400. PMID 20732961 DOI: 10.1158/1078-0432.Ccr-10-0640 |
0.349 |
|
| 2009 |
Hauck P, Chao BH, Litz J, Krystal GW. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Molecular Cancer Therapeutics. 8: 883-92. PMID 19372561 DOI: 10.1158/1535-7163.Mct-08-1118 |
0.347 |
|
| 2007 |
Rodina A, Vilenchik M, Moulick K, Aguirre J, Kim J, Chiang A, Litz J, Clement CC, Kang Y, She Y, Wu N, Felts S, Wipf P, Massague J, Jiang X, ... ... Krystal GW, et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nature Chemical Biology. 3: 498-507. PMID 17603540 DOI: 10.1038/Nchembio.2007.10 |
0.363 |
|
| 2006 |
Litz J, Krystal GW. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Molecular Cancer Therapeutics. 5: 1415-22. PMID 16818499 DOI: 10.1158/1535-7163.Mct-05-0503 |
0.36 |
|
| 2005 |
Krystal GW. Receptor tyrosine kinase mutations: molecular indicators for therapeutic response or signposts marking important signaling pathways? Cancer Biology & Therapy. 4: 1417-8. PMID 16322688 DOI: 10.4161/Cbt.4.12.2360 |
0.357 |
|
| 2005 |
Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1563-71. PMID 15746061 DOI: 10.1158/1078-0432.Ccr-04-1544 |
0.516 |
|
| 2004 |
Litz J, Sakuntala Warshamana-Greene G, Sulanke G, Lipson KE, Krystal GW. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer (Amsterdam, Netherlands). 46: 283-91. PMID 15541812 DOI: 10.1016/j.lungcan.2004.05.005 |
0.35 |
|
| 2004 |
Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, García-Echeverría C, Krystal GW. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Molecular Cancer Therapeutics. 3: 527-35. PMID 15141010 |
0.446 |
|
| 2004 |
Krystal GW. Imatinib mesylate (STI571) for myeloid malignancies other than CML. Leukemia Research. 28: S53-9. PMID 15036942 DOI: 10.1016/j.leukres.2003.10.003 |
0.304 |
|
| 2003 |
Yu C, Subler M, Rahmani M, Reese E, Krystal G, Conrad D, Dent P, Grant S. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biology & Therapy. 2: 544-51. PMID 14614324 DOI: 10.4161/Cbt.2.5.454 |
0.495 |
|
| 2003 |
Litz J, Carlson P, Warshamana-Greene GS, Grant S, Krystal GW. Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 4586-94. PMID 14555534 |
0.335 |
|
| 2003 |
Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P, Grant S. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood. 102: 1824-32. PMID 12738674 DOI: 10.1182/Blood-2002-12-3785 |
0.574 |
|
| 2003 |
Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Research. 63: 2118-26. PMID 12727828 |
0.503 |
|
| 2003 |
Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P, Grant S. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Research. 63: 1822-33. PMID 12702569 |
0.562 |
|
| 2002 |
Lloyd KP, Krystal GW. Role of small-molecule kit receptor tyrosine kinase inhibitors in the treatment of small-cell lung cancer. Clinical Lung Cancer. 3: 213-8. PMID 14662046 DOI: 10.3816/Clc.2002.N.005 |
0.421 |
|
| 2002 |
Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Molecular Cancer Therapeutics. 1: 913-22. PMID 12481412 |
0.426 |
|
| 2002 |
Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells Clinical Cancer Research. 8: 2976-2984. PMID 12231544 |
0.422 |
|
| 2002 |
Arteaga CL, Khuri F, Krystal G, Sebti S. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Seminars in Oncology. 29: 15-26. PMID 11894010 DOI: 10.1053/Sonc.2002.31524 |
0.494 |
|
| 2002 |
Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Research. 62: 188-99. PMID 11782377 |
0.505 |
|
| 2002 |
Krystal GW. Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 4: 16-21. PMID 11512148 DOI: 10.1054/DRUP.2000.0176 |
0.405 |
|
| 2000 |
Bondzi C, Grant S, Krystal GW. A novel assay for the measurement of Raf-1 kinase activity. Oncogene. 19: 5030-3. PMID 11042690 DOI: 10.1038/Sj.Onc.1203862 |
0.583 |
|
| 2000 |
Bondzi C, Litz J, Dent P, Krystal GW. Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 11: 305-14. PMID 10910097 |
0.606 |
|
| 1999 |
Hines SJ, Litz JS, Krystal GW. Coexpression of c-kit and stem cell factor in breast cancer results in enhanced sensitivity to members of the EGF family of growth factors Breast Cancer Research and Treatment. 58: 1-10. PMID 10634512 DOI: 10.1023/A:1006272527435 |
0.56 |
|
| 1999 |
Tian Q, Frierson HF, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors American Journal of Pathology. 154: 1643-1647. PMID 10362788 DOI: 10.1016/S0002-9440(10)65419-3 |
0.425 |
|
| 1998 |
Maguer-Satta V, Burl S, Liu L, Damen J, Chahine H, Krystal G, Eaves A, Eaves C. BCR-ABL accelerates C2-ceramide-induced apoptosis. Oncogene. 16: 237-48. PMID 9464542 DOI: 10.1038/Sj.Onc.1201533 |
0.378 |
|
| 1998 |
Park GH, Plummer HK, Krystal GW. Selective Sp1 Binding Is Critical for Maximal Activity of the Human c-kit Promoter Blood. 92: 4138-4149. DOI: 10.1182/Blood.V92.11.4138.423K44_4138_4149 |
0.347 |
|
| 1997 |
Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, Grant S. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Molecular Pharmacology. 52: 1000-9. PMID 9396780 DOI: 10.1124/Mol.52.6.1000 |
0.468 |
|
| Show low-probability matches. |